Xeris Biopharma (XERS) News Today $3.23 +0.01 (+0.31%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Xeris Biopharma (XERS) to Release Quarterly Earnings on FridayXeris Biopharma (NASDAQ:XERS) will be releasing earnings before the market opens on Friday, November 8, Zacks reports.November 1 at 9:27 AM | marketbeat.comXeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024October 31 at 8:00 AM | businesswire.comXeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It AttractiveOctober 25, 2024 | seekingalpha.comOppenheimer Remains a Buy on Xeris Pharmaceuticals (XERS)October 23, 2024 | markets.businessinsider.comSeveral Insiders Invested In Xeris Biopharma Holdings Flagging Positive NewsOctober 9, 2024 | finance.yahoo.comXeris Biopharma: Time For A ReassessmentOctober 9, 2024 | seekingalpha.comXeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)October 4, 2024 | businesswire.comXTX Topco Ltd Sells 223,267 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)XTX Topco Ltd lessened its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 87.5% in the second quarter, according to its most recent filing with the SEC. The firm owned 31,782 shares of the company's stock after selling 223,267 shares during the period. XTX TopcoOctober 2, 2024 | marketbeat.comRenaissance Technologies LLC Acquires 342,300 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Renaissance Technologies LLC increased its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 33.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,351,640 shOctober 1, 2024 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) most popular amongst individual investors who own 53% of the shares, institutions hold 43%September 12, 2024 | finance.yahoo.com3 Penny Stocks to Buy With $500August 30, 2024 | 247wallst.comXERS Jan 2025 5.000 callAugust 24, 2024 | ca.finance.yahoo.comXeris to Participate in Upcoming Investor ConferencesAugust 23, 2024 | finance.yahoo.comXERS Sep 2024 5.000 put (XERS240920P00005000)August 18, 2024 | finance.yahoo.comBrokers Offer Predictions for Xeris Biopharma Holdings, Inc.'s Q3 2024 Earnings (NASDAQ:XERS)Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Stock analysts at HC Wainwright reduced their Q3 2024 earnings estimates for shares of Xeris Biopharma in a research note issued on Wednesday, August 14th. HC Wainwright analyst O. Livnat now expects that the company will earn ($0.10) pAugust 16, 2024 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) to Post FY2027 Earnings of $0.27 Per Share, HC Wainwright ForecastsXeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Equities research analysts at HC Wainwright lowered their FY2027 EPS estimates for Xeris Biopharma in a report issued on Wednesday, August 14th. HC Wainwright analyst O. Livnat now forecasts that the company will post earnings of $0.27August 15, 2024 | marketbeat.comMore Than $20M Bet On Precigen? Check Out These 3 Stocks Under $5 Insiders Are Aggressively BuyingAugust 14, 2024 | benzinga.comXeris Biopharma And 2 Other Penny Stocks Insiders Are BuyingAugust 14, 2024 | msn.comInsider Buying: Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Acquires 4,285 Shares of StockAugust 13, 2024 | insidertrades.comVanguard Group Inc. Grows Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Vanguard Group Inc. grew its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 7.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,606,242 shares of the company's stock after acquiring an additiAugust 13, 2024 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Buys $10,155.45 in StockXeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) Director John P. Schmid acquired 4,285 shares of Xeris Biopharma stock in a transaction on Friday, August 9th. The stock was acquired at an average price of $2.37 per share, with a total value of $10,155.45. Following the purchase, the director now directly owns 20,685 shares in the company, valued at $49,023.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.August 12, 2024 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPSXeris Biopharma (NASDAQ:XERS - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.01. Xeris Biopharma had a negative return on equity of 16,662.63% and a negative net margin of 37.58%. The company had revenue of $48.07 million during the quarter, compared to the consensus estimate of $46.80 million. During the same period last year, the business earned ($0.14) EPS.August 10, 2024 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | msn.comXERS Stock Earnings: Xeris Biopharma Holdings Beats EPS, Beats Revenue for Q2 2024August 8, 2024 | investorplace.comXeris Biopharma Reports Second Quarter 2024 Financial ResultsAugust 8, 2024 | finance.yahoo.comCraig-Hallum Keeps Their Buy Rating on Xeris Pharmaceuticals (XERS)August 7, 2024 | markets.businessinsider.comXERS Aug 2024 2.000 put (XERS240816P00002000)July 24, 2024 | finance.yahoo.comLeerink Partnrs Comments on Xeris Biopharma Holdings, Inc.'s Q2 2024 Earnings (NASDAQ:XERS)Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Leerink Partnrs boosted their Q2 2024 earnings per share estimates for Xeris Biopharma in a note issued to investors on Tuesday, July 9th. Leerink Partnrs analyst R. Ruiz now expects that the company will earn ($0.11) per share for theJuly 11, 2024 | marketbeat.comXeris Biopharma unveils CEO succession plan, John Shannon to lead companyJuly 8, 2024 | proactiveinvestors.comXeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)July 3, 2024 | businesswire.comInvenomic Capital Management LP Takes Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Invenomic Capital Management LP bought a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 568,619 shares of the company's stock, valued at approxiJune 11, 2024 | marketbeat.comXeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing's Syndrome Patients at ENDO 2024June 3, 2024 | businesswire.comXeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)May 30, 2024 | businesswire.comXeris to Participate in the Jefferies Global Healthcare ConferenceMay 30, 2024 | businesswire.comStrong Operational Performance and Promising Prospects Affirm Buy Rating for Xeris PharmaceuticalsMay 10, 2024 | markets.businessinsider.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comXeris Biopharma Holdings Inc (XERS) Q1 2024 Earnings: Revenue Growth Amidst ChallengesMay 10, 2024 | finance.yahoo.comPiper Sandler Reaffirms Overweight Rating for Xeris Biopharma (NASDAQ:XERS)Piper Sandler reissued an "overweight" rating and set a $3.00 price target (down from $4.00) on shares of Xeris Biopharma in a report on Friday.May 10, 2024 | marketbeat.comXeris Biopharma Holdings First Quarter 2024 Earnings: Misses ExpectationsMay 10, 2024 | finance.yahoo.comQ1 2024 Xeris Biopharma Holdings Inc Earnings CallMay 10, 2024 | finance.yahoo.comCraig-Hallum Reaffirms Their Buy Rating on Xeris Pharmaceuticals (XERS)May 9, 2024 | markets.businessinsider.comXERS Stock Earnings: Xeris Biopharma Holdings Misses EPS, Misses Revenue for Q1 2024May 9, 2024 | investorplace.comXeris Biopharma sees 1Q revenue jump on strength of product salesMay 9, 2024 | proactiveinvestors.comXeris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.02, revenue of $40.64M misses by $1.17MMay 9, 2024 | msn.comXeris Biopharma Reports First Quarter 2024 Financial Results and Recent EventsMay 9, 2024 | finance.yahoo.comXERS Xeris Biopharma Holdings, Inc.May 9, 2024 | seekingalpha.comHere's what Wall Street expects from Xeris Biopharma's earnings reportMay 8, 2024 | markets.businessinsider.comXeris Biopharma and Beta Bionics join forces to develop dual-hormone pump for diabetesMay 6, 2024 | proactiveinvestors.comXeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta BionicsMay 6, 2024 | businesswire.comPleasing Signs As A Number Of Insiders Buy Xeris Biopharma Holdings StockMay 2, 2024 | finance.yahoo.com Get Xeris Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here XERS Media Mentions By Week XERS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XERS News Sentiment▼0.000.43▲Average Medical News Sentiment XERS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XERS Articles This Week▼22▲XERS Articles Average Week Get Xeris Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VERU News MBIO News MIRM News RXRX News ARVN News WVE News TECX News OCUL News NAMS News IMCR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XERS) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xeris Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
